Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Baxter International’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028962
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Cost of sales | 1,810 | 1,764 |
| Gross margin | 891 | 861 |
| Selling, general and administrative expenses | 728 | 703 |
| Research and development expenses | 139 | 140 |
| Other operating income, net | (42) | (40) |
| Operating income | 66 | 58 |
| Interest expense, net | 66 | 64 |
| Other (income) expense, net | 6 | (3) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Baxter International's R&D?
- Baxter International (BAX) reported R&D of $139M in Q1 2026.
- How has Baxter International's R&D changed year-over-year?
- Baxter International's R&D decreased by 0.7% year-over-year, from $140M to $139M.
- What is the long-term trend for Baxter International's R&D?
- Over 4 years (2021 to 2025), Baxter International's R&D has grown at a -0.6% compound annual growth rate (CAGR), from $531M to $518M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Baxter International's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude